<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03754192</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180011</org_study_id>
    <nct_id>NCT03754192</nct_id>
  </id_info>
  <brief_title>Perfusion and Dual Energy Computer Tomography in Hepatocellular Carcinoma</brief_title>
  <acronym>PERCAHEC</acronym>
  <official_title>Prediction Value of Perfusion and Dual Energy Computer Tomography for Microvascular Invasion in Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the hepatic perfusion computer tomography and dual
      energy computer tomography in the assessment of tumor characterization of Hepatocellular
      carcinoma in patients with resectable Hepatocellular carcinoma by comparing the quantitative
      parameters computer tomography obtained with the pathological data of the surgical specimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dual-energy computer tomography and perfusion computer tomography (General Electric
      revolution Hight definition Gemstone™ Spectral Imaging) will be performed in all patients.
      Iodine concentration and quantitative perfusion parameters of the Hepatocellular carcinoma
      and surrounding liver parenchyma data will be compared with the pathological results.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dual-energy computed tomography and perfusion computed tomography</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pefusion parameters</measure>
    <time_frame>5 minutes</time_frame>
    <description>correlation between pre-operative imaging data and histological data of Hepatocellular carcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological examination</measure>
    <time_frame>1 month</time_frame>
    <description>Compare data obtained in perfusion computer tomography to the imaging data and to the Histological differentiation grades</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>perfusion computed tomography</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Will be realsed before liver surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>perfusion Computed Tomography</intervention_name>
    <description>Will be carried before liver surgery</description>
    <arm_group_label>perfusion computed tomography</arm_group_label>
    <other_name>Computed tomography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of Hepatocellular carcinoma made according to the guidelines of the
             American Association for the study of the Liver

          -  Affiliation to a national health insurance

          -  An indication for hepatic resection during the decision-making stage

          -  A request for a pre-operative Computer Tomography in our radiology unit

          -  An affiliation to a social security

          -  Informed consent given by the patient

        Exclusion Criteria:

          -  Previous treatments of Hepatocellular carcinoma (medicated or surgical)

          -  Patient under tutorship or curatorship

          -  Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LEWIN MAITE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LEWIN MAITE, MD, Phd</last_name>
    <phone>00 (33) 6 11 15 06 17</phone>
    <email>maite.lewin@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DA-MOTA-FERREIRA Jean-Manuel, Radiologic</last_name>
    <phone>00 (33) 145592474</phone>
    <email>jean-manuel.da-mota-ferreira@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LEWIN MAITE, MD, PhD</last_name>
      <phone>00 (33) 6 11 15 06 17</phone>
      <email>maite.lewin@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perfusion computer tomography</keyword>
  <keyword>dual-energy computer tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

